ASCO 2022

Transatlantic differences in ADC side effects…

What are the cosenquences of the new OS data for CDK4/6…

More data needed: Are the results clinical meaningful?…

Paradigm shift in breast cancer: Where do we use the…

Patients perspectives: ADCs - how do manage the new,…

What clincial value has statistical signifcance? How…

ADCs & CDK4/6i - paradigm shifts and therapy switches…

How to determine progress of disease? How to proceed…

Oligometastasis: no advantage of additional…

Fascinating data of ADCs in breast cancer at ASCO22

Discontiunation of trial is disappointing despite…

SG may be a good option for pre-treated HR+/Her2- pts

New standard of care for HR+/Her2low patients

New agents for the clincial practice

T-DxD should be the new SoC for Her2low MBC patients

Exciting and practice changing news for HR+/Her2low MBC…

Benefit of CDK4/6 Switch after Progression

SG is a new therapy option for HR+/HER2- MBC patients

Additional administration of ribociclib improves PFS…

Impressive and practice changing data of ADCs mark the…

First evidence on benefit of CDK4/6 inhibitors beyond…

Good therapeutic option in HR+ HER2- mBC after failure…

Palbociclib - Overall survival data

Possible explanations of the negative study

Combination of ctDNA and TKa assesment may improve…

Exciting advances across a wide subset of breast…

Improvment of PFS & OS with activated alteration…

Combi SERD + Palbo reduces proliferation better than…

Gamechanger in breast cancer

Patritumab Deruxtecan: HER3-targeted ADC in HER3…

Breakthrough news with antibody drug conjugate

Disappoiting final OS data and its implications for our…

Sacituzumab govitecan improves PCr in patients with…

Revolution in the field of HR+ disease

Smart chemotherapy improves PFS

No changes in clinical practice after new CDK4/6i-data

My ASCO22 highlights in metastatic breast cancer

Practice changing data

ADC: future therapeutic option in advanced HR+/HER2 BC

New SoC for large subpopulation of breast cancer…

No effect for local treatment of metastasis

Option for overcoming endocrine resistance?

Noutăți inovatoare cu conjugatul de medicamente cu…

I nuovi impressionanti risultati degli ADC a l’ASCO…

ADCs en cáncer de mama con receptores hormonales…

Novità entusiasmanti e practice changing per le…

SG come nuova opzione di cura per le pazienti con…

PALOMA2 e MAINTAIN: cosa cambia nella pratica clinica?

Les nouvelles données impressionnantes des ADC à l’ASCO…

Una rivoluzione per il tumore mammario…

La valutazione combinata di ctDNA e TKa può aiutare a…

Pierwsze dane nt. skuteczności inhibitorów CDK4/6 po…

Nowy standard dla znaczącej subopulacji chorych na raka…

CT benefit for elderly patients, if they are able to…

Neoadjuvant Pembro decreased RCB. SG - first promising…

Long term overall survival benefit of Denosumab in…

Adding towards deescalation in luminal A EBC by…

High concordance of local, central IHC and RT-PCR for…

Combi SERD + Palbo redzuert proliferation better than…

Molecular landscape - Part 2

Immunotherapy - Part 1

Immunotherapy - Part 2

New treatment options for METexon 14 skipping:…

COSMIC-021: Not practice-changing, but interesting…

CLN-081 is a promising new agent for EGFR exon 20…

Bispecific Antibodies - the cMET field is moving

Strategies for PD-L1 > 50%

In the second line: Options for Immunotherapy…

A chemo-free option in patients with EGFR-mutation

Promising results for pre-treated patients with…

Role of IO and chemo-IO in patients with PD-L1 > 50%

Amivantamab as a future option for METex14 patients?

CLN-081 for patients with metastatic NSCLC and an…

KRASG12C mutation: Adagrasib is comparabale to…

PD-L1 over 50%: Chemo-IO or IO?

Multiple aquired resistance mutations may drive disease…

New option in patients harboring METex14 mutation

Options after progression to chemo/IO and for KRASG12C…

Is adagrasib an alternative to sotorasib?

Nieuwe behandelopties voor METexon 14 skipping:…

CLN-081 voor patienten met gemetastaseerd NSCLC en een…

Veelbelovende resultaten voor voorbehandelde patienten…

Bispezifische Antikörper - Neues von CHRYSALIS

Segunda Linea: opciones tras resistencia a…

PD-L1 über 50 % - was tun?

COSMIC-021: Nicht praxisverändernd, aber interessante…

Die Rolle von IO und Chemo-IO bei Patienten mit PD-L1 >…

L’adagrasib, inhibiteur de la mutation KRASG12C: une…

Was tun nach Versagen einer Chemoimmun-Therapie?

Nuevas terapias para el CPCNP avanzado

Neoadjuvant and adjuvant therapy - Part 1

CheckMate-816: Neoadjuvant therapy

New treatment approaches in Stage III

A new option in neoadjuvant chemoimmunotherapy

Perspectives on multimodality

Neue Ansätze im Stadium III

No benefit for tiragolumab / novel anti-PD-1 mAB…

SCLC-Update: No benefit with Tiragolumab/Chemo-IO is…

Immuncheckpoint-inhibitor therapy

mHSPC: Transatlantic differences in genetic testing &…

PARP inhibitors in mCRPC: Do we need more genetic…

TheraP shows no difference in overall survival between…

Phase 1 study on combining LuPSMA treatment with…

PFS good surrogate endpoint for overall survival

SHR3680 - do we need a new androgen receptor inhibitor

Value of triple-therapy - complimentary study to…

Lu-PSMA in the third line

No big scoop, but encouraging results

LuPSMA & cabazitaxel are better than SoC alone

3 year overall survival of TheraP study

Lu-PSMA effective regardless of prior or concomitant…

The highlights in GU cancers of ASCO22

Arbiraterone + Olaparib: Is it synergistic?

SUV mean at PET images as a prognostic tool for PSMA…

Ongoing trial invetiagting the impact of…

SUVmean is highly predictive of better PFS and OS

ADT alone is no longer standard of care

GGT impacts PCa patients care

The efficacy of doublets in mHSPC

Surrogate endpoints in mHSPC

Frequent imaging for early detection of metastases in…

Kombination av 177-LU-PSMA-617 och pembrolizumab I Fas…

Kvantifiering av PMSA PET upptaget som prognostisk…

Treårs överlevnadsresultat i TheraP studien.

Pas de nouvelles sensationnelles mais des données…

Lo mas destacado en tumores GU en ASCO 2022

What are the consequences for future trial design?

EVEREST: Inisghts from the negative trial

The relevance of quality of life in kidney cancer!

Depth of remission in firstline

Importance of health related quality of life

Combi Axi + Pembro also successful with good risk…

Belzutifann shows good tumor activity in renal cancer

The highlights in GU cancers of ASCO22

Clear evidence for durable benefit for patients with…

Should we be looking at Everolimus in the future?

PSMA-PET may improve imaging of clear cell RCC

QoL & DepOR correlate with clinical outcomes - reminder…

Lo mas destacado en tumores GU en ASCO 2022

ADCs: do we enter a new era of therapy for urothelial…

New data on TKi utilization in bladder cancer

BCG failure

Investigating sasanlimab in BCG-unresponsive NMIBC

Exciting future for ADCs

Perioperative immuno-chemotherapy in MIBC

Maintenance concepts

No big scoop, but encouraging results

My highlights in localized urothelial cancer

My highlights of metastasized urothelial cancer

The highlights in GU cancers of ASCO22

ADCs: News from ASCO 2022

Lo mas destacado en tumores GU en ASCO 2022

Precision oncology - NTRK worth to search the patients

News from Sarcoma

Few testicular tumors after 5 years

Systemic therapy

Opportunities & challenges of cancer genetics